SecBot SecBot
8-K ·Filed Feb 26, 2026

PHAT

Phathom Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001193125-26-073377
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of strong revenue growth, successful $130 million capital raise, and clear path to profitability in 2026 makes PHAT a compelling biotech investment. Traders should monitor prescription growth trends and the company's ability to meet its 2026 guidance.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.56
T+0 close · Feb 26, 2026 · via day close
Latest settled
−14.60%
T+60 · $11.58
Vs SPY
−22.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $13.56entry
  2. T+1 · 9mo ago −7.37%α −6.92% · $12.56
  3. T+5 · 9mo ago −20.80%α −19.67% · $10.74
  4. T+20 · 8mo ago −20.43%α −14.03% · $10.79
  5. T+60 · 6mo ago −14.60%α −22.35% · $11.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phathom Pharmaceuticals reported strong financial results for Q4 and full year 2025, with revenue of $57.6 million in Q4 and $175.1 million for the full year, representing a 217% increase from 2024. The company also announced $130 million in gross proceeds from an equity offering and provided 2026 guidance with expected operating profitability beginning in Q3 2026.

Key Financial Metrics

Revenue
$175.1M
+217.0% YoY
Adj. EPS
$-0.08
GAAP: $-0.29
Guidance
$320-$345 million
initiated
Gross Margin
80%

Key Facts

  • Q4 2025 revenue was $57.6 million, up from $29.7 million in Q4 2024
  • Full year 2025 revenue was $175.1 million, a 217% increase from $55.3 million in 2024
  • Company completed $130 million equity offering in January 2026
  • Provided 2026 guidance with net revenues of $320-345 million and expected operating profitability beginning in Q3 2026
  • Over 1.1 million total VOQUEZNA prescriptions filled as of February 13, 2026

Financial Impact

Revenue increased 217% year-over-year to $175.1 million in 2025, with 2026 guidance projecting $320-345 million in net revenues

revenueoperating expensescash position

Segment Breakdown

SegmentRevenueGrowth
VOQUEZNA$175.1M+217.0%

Risk Factors

  • Forward-looking statements about achieving profitability in Q3 2026
  • Dependence on continued VOQUEZNA prescription growth
  • Potential competition in the GERD treatment market

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073377
Document: d119012d8k.htm0001193125-26-073377
Document: 0001193125-26-073377-index-headers.html0001193125-26-073377
Document: 0001193125-26-073377-index.html0001193125-26-073377
Document: 0001193125-26-073377.txt0001193125-26-073377

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026